Amesite INC

Amesite Inc. has entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing for the sale of its common stock up to a specified aggregate offering price.

Amesite Inc. announced that its stockholders approved an amendment to the 2018 Equity Incentive Plan, increasing available shares by 1,000,000.

Amesite Inc. announced a significant new enterprise customer for its NurseMagic platform, representing its largest deployment to date and validating its AI-native infrastructure strategy.

Amesite Inc. announced the pricing of concurrent registered direct and private offerings, raising approximately $2.6 million in gross proceeds, with additional potential proceeds from warrant exercises.

Amesite Inc. announced a 69% quarter-over-quarter revenue increase in Q2 2026, alongside reduced spending and plans to launch an AI-powered Electronic Medical Record platform by 2026.

Amesite Inc. received a Nasdaq deficiency letter for failing to meet minimum stockholders' equity and other listing standards, initiating a 45-day period to submit a compliance plan.

Amesite Inc. reported increased revenue and reduced net loss for the nine months ended March 31, 2026, while addressing Nasdaq listing compliance.

Amesite Inc. significantly narrowed its net loss and increased revenue in Q1 2026, driven by a strategic shift to AI-driven healthcare solutions, despite ongoing 'going concern' doubts.

Amesite Inc. reports a net loss for Q3 2025, but highlights a strategic shift towards AI-driven solutions and a reduction in cash burn.

Amesite Inc. reports a decrease in revenue for the six months ended December 31, 2024, alongside a strategic pivot to grow its customer base and reduce losses.

Amesite Inc. has amended its quarterly report to disclose material weaknesses in its internal controls over financial reporting as of June 30, 2024.

Amesite Inc. reports a net loss of $908,045 for the quarter ended September 30, 2024, alongside a strategic pivot towards AI-powered solutions and cost reductions.

Amesite Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended June 30, 2025, to include detailed information on directors, executive compensation, and corporate governance previously omitted.

Amesite Inc. shifts its core business to AI-powered healthcare solutions with NurseMagic, reporting reduced net losses but facing substantial doubt about its ability to continue as a going concern.

Amesite Inc. has amended its annual report to disclose material weaknesses in its internal control over financial reporting as of June 30, 2024.

Amesite Inc.'s annual report highlights a strategic shift towards AI-powered solutions in education and healthcare, alongside efforts to reduce costs and secure sustainable revenue streams.

Amesite Inc. reports that Chief Financial Officer Sarah Berman acquired 10,000 stock options with an exercise price of $1.14.

Amesite Inc. Chief Financial Officer, Sarah Berman, acquired stock options for 2,500 shares of common stock on May 22, 2025, as detailed in a Form 4 filing.

J. Michael Losh, a Director at Amesite Inc., has been granted 10,902 deferred stock units as compensation for services.

Director Barbie Brewer of Amesite Inc. has reported the acquisition of restricted stock units as deferred compensation for services rendered.

Amesite Inc. CEO Ann Marie Sastry acquired 174,216 shares of common stock and associated warrants in a private placement.

Amesite Inc. Director George Parmer acquired 243,902 shares of common stock and an equivalent number of warrants in a private placement.

Amesite Inc. has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held on July 13, 2026.

Richard Ogawa and Anthony Barkett have resigned from Amesite Inc.'s Board of Directors prior to the Annual Meeting of Stockholders.

Amesite Inc. has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Amesite Inc. has scheduled its annual stockholder meeting for January 21, 2025, to elect directors and ratify the appointment of its independent auditor.

Amesite Inc. is asking stockholders to approve an amendment to its 2018 Equity Incentive Plan to increase the number of shares available for issuance by 508,488.

Amesite Inc. has filed an amendment to its S-1 registration statement, primarily to correct a technical error regarding its auditor's consent filing date.

Amesite Inc. has filed a registration statement for the resale of up to 4,836,245 shares of common stock issuable upon the exercise of various warrants.

Amesite Inc. has filed a registration statement for a public offering of common stock and warrants to raise approximately $4.47 million for working capital.

Intracoastal Capital LLC and its principals have filed a Schedule 13G reporting a 4.99% beneficial ownership stake in Amesite Inc. following recent securities purchase agreements.